Novartis; local clinical study for combined anti-hypertension drugs.

Published: 2005-05-10 06:56:00

Updated: 2005-05-10 06:56:00

Novartis Korea announced on May 4 to conduct a local clinical study for a combined anti-hypertension drug with Diovan (valsartan), an angiotensin receptor blocker, and Amodipin (amlodipin camsylate), a calcium channel blocker to check its efficacy and safety of Korean patients.

About 130 candidate patients for the study include those who hardly reach the target blood pressure of 140/90mgHg. ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.